Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 155027 - 155027
Опубликована: Дек. 11, 2023
Язык: Английский
Molecular Biomedicine, Год журнала: 2025, Номер 6(1)
Опубликована: Янв. 6, 2025
Cancer remains a leading cause of mortality globally and major health burden, with chemotherapy often serving as the primary therapeutic option for patients advanced-stage disease, partially compensating limitations non-curative treatments. However, emergence resistance significantly limits its efficacy, posing clinical challenge. Moreover, heterogeneity mechanisms across cancer types complicates development universally effective diagnostic approaches. Understanding molecular chemoresistance identifying strategies to overcome it are current research focal points. This review provides comprehensive analysis key underlying resistance, including drug efflux, enhanced DNA damage repair (DDR), apoptosis evasion, epigenetic modifications, altered intracellular metabolism, role stem cells (CSCs). We also examine specific causes in highlight various targets involved resistance. Finally, we discuss aiming at overcoming such combination therapies, targeted treatments, novel delivery systems, while proposing future directions this evolving field. By addressing these barriers, lays foundation more therapies aimed mitigating
Язык: Английский
Процитировано
5
Pathology - Research and Practice, Год журнала: 2023, Номер 248, С. 154715 - 154715
Опубликована: Июль 27, 2023
Язык: Английский
Процитировано
32
Pathology - Research and Practice, Год журнала: 2023, Номер 249, С. 154771 - 154771
Опубликована: Авг. 19, 2023
Язык: Английский
Процитировано
24
Pathology - Research and Practice, Год журнала: 2023, Номер 250, С. 154817 - 154817
Опубликована: Сен. 13, 2023
Язык: Английский
Процитировано
24
Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 155007 - 155007
Опубликована: Дек. 4, 2023
Язык: Английский
Процитировано
23
World Journal of Gastrointestinal Oncology, Год журнала: 2024, Номер 16(1), С. 13 - 29
Опубликована: Янв. 9, 2024
Gallbladder (GB) carcinoma, although relatively rare, is the most common biliary tree cholangiocarcinoma with aggressiveness and poor prognosis. It closely associated cholelithiasis long-standing large (> 3 cm) gallstones in up to 90% of cases. The other main predisposing factors for GB carcinoma include molecular such as mutated genes, wall calcification (porcelain) or mainly mucosal microcalcifications, polyps ≥ 1 cm size. Diagnosis made by ultrasound, computed tomography (CT), and, more precisely, magnetic resonance imaging (MRI). Preoperative staging great importance decision-making regarding therapeutic management. based on MRI findings, leading technique liver metastasis imaging, enhanced three-phase CT angiography, angiography major vessel assessment. also necessary use positron emission (PET)-CT 18F-FDG PET-MRI accurately detect metastases any occult deposits active metabolic uptake. Staging laparoscopy may dissemination not otherwise found 20%-28.6% Multimodality treatment needed, including surgical resection, targeted therapy biological agents according testing gene mapping, chemotherapy, radiation therapy, immunotherapy. understand updated guidelines current options. extent intervention depends disease stage, ranging from simple cholecystectomy (T1a) extended resections (T1b), wide lymph node resection every case IV-V segmentectomy (T2), hepatic trisegmentectomy hepatectomy accompanied hepaticojejunostomy Roux-Y, adjacent organ if (T3). Laparoscopic robotic surgery shows fewer postoperative complications equivalent oncological outcomes when compared open surgery, but much attention must be paid avoiding injuries. In addition novel along immunotherapy recent improvements radiotherapy chemotherapy (neoadjuvant-adjuvant capecitabine, cisplatin, gemcitabine) have yielded promising results even inoperable cases calling palliation (T4). Thus, individualized applied.
Язык: Английский
Процитировано
13
Current Gene Therapy, Год журнала: 2024, Номер 24(3), С. 193 - 207
Опубликована: Фев. 4, 2024
With the discovery of CRISPR-Cas9, drug development and precision medicine have undergone a major change. This review article looks at new ways that CRISPR-based therapies are being used how they changing way is done. CRISPR technology's ability to precisely flexibly edit genes has opened up find, validate, develop targets. Also, it made for personalized gene therapies, precise editing, advanced screening techniques, all which hold great promise treating wide range diseases. In this article, we look latest research clinical trials show could be treat genetic diseases, cancer, infectious other hard-to-treat conditions. However, ethical issues problems with regulations also discussed in relation shows important use them safely responsibly. As continues change drugs used, shines light on amazing things been done what future might rapidly field.
Язык: Английский
Процитировано
10
Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2024, Номер 397(12), С. 9549 - 9571
Опубликована: Июль 19, 2024
Язык: Английский
Процитировано
9
Pathology - Research and Practice, Год журнала: 2023, Номер 249, С. 154763 - 154763
Опубликована: Авг. 14, 2023
Язык: Английский
Процитировано
21
Pathology - Research and Practice, Год журнала: 2023, Номер 250, С. 154790 - 154790
Опубликована: Сен. 6, 2023
Язык: Английский
Процитировано
18